Eli Lilly follows J&J in suing Biden administration over 340B rebates
Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead of giving them upfront discounts on 340B drugs.
Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead of giving them upfront discounts on 340B drugs.
In the third quarter, the seven major publicly traded insurers’ medical loss ratios increased an average of 3.3 percentage points year over year — a major jump in medical costs.
“Do to others what you would want done to yourself,” Medicaid director Daniel Tsai said Thursday when asked about advice for his replacement in Trump’s HHS. Trump is expected to cut Medicaid eligibility and funding.
The Franklin, Tennessee-based operator has not purchased a hospital in years. That may soon change as CHS’ margins improve.
The nomination of a prominent vaccine skeptic to the head of the nation’s largest healthcare program is expected to alarm some public health experts.
Regulators’ assessment of customer support centers has spurred recent lawsuits from UnitedHealthcare, Centene and Humana. But the metric “is going to have a smaller weighting on star ratings moving forward,” the director of Medicare said.
The findings could reassure policymakers concerned that virtual care could increase unnecessary or wasteful services.
Mass General Brigham, Emory and other providers will assess different AI models from companies like Google, Microsoft and Amazon.
The drug distributor will buy a majority stake in gastroenterology practice management group GI Alliance and purchase Advanced Diabetes Supply Group in deals that should close in early 2025.
Fasola is the second-highest paid executive at the insurer, trailing only CEO Sarah London.